IBIO – iBio Inc
iBio, Inc.IBIO
$0.824Name : iBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $40,945,068.00
EPSttm : -0.32
iBio, Inc.
$0.824
5.67%$0.044
IBIO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.25
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.04
EPS Last/This Y
-0.06
EPS This/Next Y
-0.24
Price
0.82
Target Price
5.53
Analyst Recom
1.12
Performance Q
-41.13
Upside
-850.0%
Beta
1.47
Ticker: IBIO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | IBIO | 0.8902 | N/A | N/A | 0 |
| 2026-10-13 | IBIO | 0.7837 | N/A | N/A | 0 |
| 2026-10-14 | IBIO | 0.7772 | N/A | N/A | 0 |
| 2026-10-15 | IBIO | 0.7704 | N/A | N/A | 0 |
| 2026-10-16 | IBIO | 0.7632 | N/A | N/A | 0 |
| 2026-10-19 | IBIO | 0.7657 | N/A | N/A | 0 |
| 2026-10-20 | IBIO | 0.8394 | N/A | N/A | 0 |
| 2026-10-21 | IBIO | 0.84 | N/A | N/A | 0 |
| 2026-10-22 | IBIO | 0.7801 | N/A | N/A | 0 |
| 2026-10-23 | IBIO | 0.722 | N/A | N/A | 0 |
| 2026-10-26 | IBIO | 0.7094 | N/A | N/A | 0 |
| 2026-10-27 | IBIO | 0.7574 | N/A | N/A | 0 |
| 2026-10-28 | IBIO | 0.7985 | N/A | N/A | 0 |
| 2026-10-29 | IBIO | 0.8099 | N/A | N/A | 0 |
| 2026-10-30 | IBIO | 0.7612 | N/A | N/A | 0 |
| 2026-11-02 | IBIO | 0.7899 | N/A | N/A | 0 |
| 2026-11-03 | IBIO | 0.812 | N/A | N/A | 0 |
| 2026-11-04 | IBIO | 0.8001 | N/A | N/A | 0 |
| 2026-11-05 | IBIO | 0.7321 | N/A | N/A | 0 |
| 2026-11-06 | IBIO | 0.7358 | N/A | N/A | 0 |
| 2026-11-09 | IBIO | 0.776 | N/A | N/A | 0 |
| 2026-11-10 | IBIO | 0.7858 | N/A | N/A | 0 |
| 2026-11-11 | IBIO | 0.8322 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | IBIO | 0.89 | 31.8 | - | -0.38 |
| 2026-10-13 | IBIO | 0.77 | 31.8 | - | -0.38 |
| 2026-10-14 | IBIO | 0.77 | 31.8 | - | -0.38 |
| 2026-10-15 | IBIO | 0.78 | 31.8 | - | -0.38 |
| 2026-10-16 | IBIO | 0.76 | 31.2 | - | -0.38 |
| 2026-10-19 | IBIO | 0.76 | 31.2 | - | -0.38 |
| 2026-10-20 | IBIO | 0.76 | 31.2 | - | -0.38 |
| 2026-10-21 | IBIO | 0.84 | 31.2 | - | -0.38 |
| 2026-10-22 | IBIO | 0.78 | 31.2 | - | -0.38 |
| 2026-10-23 | IBIO | 0.72 | 31.2 | - | -0.38 |
| 2026-10-26 | IBIO | 0.71 | 31.2 | - | -0.38 |
| 2026-10-27 | IBIO | 0.77 | 31.2 | - | -0.38 |
| 2026-10-28 | IBIO | 0.80 | 31.2 | - | -0.38 |
| 2026-10-29 | IBIO | 0.81 | 31.2 | - | -0.38 |
| 2026-10-30 | IBIO | 0.76 | 31.2 | - | -0.38 |
| 2026-11-02 | IBIO | 0.80 | 31.2 | - | -0.38 |
| 2026-11-03 | IBIO | 0.82 | 31.2 | - | -0.38 |
| 2026-11-04 | IBIO | 0.80 | 31.2 | - | -0.38 |
| 2026-11-05 | IBIO | 0.73 | 31.2 | - | -0.38 |
| 2026-11-06 | IBIO | 0.73 | 31.2 | - | -0.38 |
| 2026-11-09 | IBIO | 0.80 | 31.2 | - | -0.38 |
| 2026-11-10 | IBIO | 0.78 | 31.2 | - | -0.38 |
| 2026-11-11 | IBIO | 0.82 | 31.2 | - | -0.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-13 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-14 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-15 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-16 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-19 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-20 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-21 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-22 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-23 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-26 | IBIO | 0.00 | 16.62 | 7.55 |
| 2026-10-27 | IBIO | 0.00 | 16.62 | 6.71 |
| 2026-10-28 | IBIO | 0.00 | 16.62 | 6.71 |
| 2026-10-29 | IBIO | 0.00 | 16.62 | 6.71 |
| 2026-10-30 | IBIO | 0.00 | 16.62 | 6.71 |
| 2026-11-02 | IBIO | 0.00 | 16.08 | 6.71 |
| 2026-11-03 | IBIO | 0.00 | 16.08 | 6.71 |
| 2026-11-05 | IBIO | 0.00 | 16.08 | 6.71 |
| 2026-11-06 | IBIO | 0.00 | 16.08 | 6.71 |
| 2026-11-09 | IBIO | 0.00 | 16.11 | 6.71 |
| 2026-11-10 | IBIO | 0.00 | 16.11 | 6.71 |
| 2026-11-11 | IBIO | 0.00 | 16.11 | 7.25 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.08
Avg. EPS Est. Next Quarter
-0.08
Insider Transactions
Institutional Transactions
16.11
Beta
1.47
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
32
Growth Score
25
Sentiment Score
21
Actual DrawDown %
99.8
Max Drawdown 5-Year %
-99.9
Target Price
5.53
P/E
Forward P/E
PEG
P/S
46.88
P/B
0.67
P/Free Cash Flow
EPS
-0.4
Average EPS Est. Cur. Y
-0.38
EPS Next Y. (Est.)
-0.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3244.19
Relative Volume
0.51
Return on Equity vs Sector %
-64.9
Return on Equity vs Industry %
-45.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
◆
IBIO
Healthcare
$0.82
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.8
Range 1M
47.6%
Sup Dist
6.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-6.3%
EPS NY
-60%
52W%
4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+574.4% upside
Upside
+574.4%
Quality
32
IBIO — P/E HistoricalBiotechnology
iBio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 23
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
IBIO
Latest News
—
Caricamento notizie per IBIO…
stock quote shares IBIO – iBio Inc Stock Price stock today
news today IBIO – iBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch IBIO – iBio Inc yahoo finance google finance
stock history IBIO – iBio Inc invest stock market
stock prices IBIO premarket after hours
ticker IBIO fair value insiders trading